Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2024-11-18 00:00:00 ET · period of report 2024-11-14 · accession 0000905148-24-003225 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-18 | 2024-11-14 | ACRV | Gamelin Erick | Chief Development Off | F - Tax | $7.92 | -402 | 17.0K | -2% | -$3,184 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-14 | F | D | 402 | $7.92 | 16,961 | D | — | — |